Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.

por Bakker, M., Droz, J. P., Hanauske, A. R., Verweij, J., van Oosterom, A. T., Groen, H. J., Pacciarini, M. A., Domenigoni, L., van Weissenbruch, F., Pianezzola, E., de Vries, E. G.
Publicado 1998